UpStream Bio UPB 深 沪
等待开盘 05-14 09:30:00 美东时间
8.99
+0.040
+0.45%
华盛通- 最 高9.055
- 今 开8.96
- 成交量 45.82万股
- 最 低 8.805
- 昨 收 8.95
- 总市值 4.89亿
- 52周最高 33.68
- 市盈率 静 --
- 换手率 0.84%
- 52周最低 7.25
- 委 比 79.86%
- 总股本 5442.00万
- 历史最高 33.68
- 量 比 1.16
- 振 幅 2.79%
- 历史最低 5.14
- 每 手 1
- 风险率 7.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Upstream Bio Q1 EPS $(0.75) Beats $(0.77) Estimate, Sales $1.034M Beat $442.000K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 47.06 percent decrease over losses of $(0.51) per share from the
05-13 19:12
Upstream Bio Announces Presentation Of New Data From Phase 2 VIBRANT Trial At American Thoracic Society Meeting On May 18
The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic
04-17 19:07
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker
Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.
04-07 19:02
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
Upstream Bio Plans To Initiate Dosing In Phase 3 Trials In Both Severe Asthma And CRSwNP In Q1 2027
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP –– Company plans to initiate
03-26 19:19
美股牛股 | OCUGEN飙升近30%，机构首次覆盖该公司并给予高额目标价；纳微半导体大涨近25%
OCUGEN飙升近30%，机构首次覆盖该公司并给予高额目标价；纳微半导体大涨近25%，推出适用于人工智能数据中心的两款新产品>>
03-12 16:40
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers American Well (NYSE:AMWL) stock moved upwards by 31.2% to $5.68 during...
02-14 01:05
Upstream Bio Releases Topline Data From Phase 2 VALIANT Trial Of Verekitug For Severe Asthma, Meeting The Primary Endpoint Of Annualized Asthma Exacerbation Rate
Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.Verekitug also delivered clinically meaningful
02-11 19:04
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Mizuho Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $51
Mizuho analyst Joseph Catanzaro initiates coverage on Upstream Bio (NASDAQ:UPB) with a Outperform rating and announces Price Target of $51.
2025-12-18 17:36
